Focused on discovering and developing small‑molecule therapies for metabolic and cardiovascular diseases, the company operates as a clinical‑stage biopharmaceutical developer with a pipeline built from its proprietary gene‑science research platform. Its lead programs include sotagliflozin, studied f...
1 member of Congress has disclosed 3 trades in Lexicon Pharmaceuticals Inc. (LXRX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-05-28 | Rohit Khanna | sell | $1K – $15K |
| 2025-04-23 | Rohit Khanna | sell | $1K – $15K |
| 2025-03-04 | Rohit Khanna | sell | $1K – $15K |